European patent granted for IMP321 & antibody combinations
Filed with ASX · · 2 pages · English
Story so far
Earlier from Immutep
- Immutep granted European patent for IMP321
- Positive interim TACTI-mel data presented at SITC
- Immutep enters into collaboration with Pfizer & Merck KGaA
- Progress towards clinical development of IMP761
- Appendix 4E & 2018 Full Year Statutory Accounts
Later from Immutep
- Cleansing prospectus for issue of warrants
- Immutep enters into collaboration with CYTLIMIC
- Half Year Accounts
- TACTI-mel data presented at World Immunotherapy Congress
- Immutep doses First Patient in TACTI-002 Phase II Trial
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep